期刊文献+

银杏叶片联合培磊能治疗血管性痴呆 被引量:1

GINKGO LEAVES ASSOCIATED WITH PERENAN TREATING VASCULAR DEMENTIA
下载PDF
导出
摘要 目的评价银杏叶片和培磊能联合用药治疗血管性痴呆的疗效及安全性。方法采用病例对照研究,将82例血管性痴呆患者,随机分为银杏叶片联合培磊能观察组42例与脑复康对照组40例,全部患者在用药前、用药后6个月,采用简明精神状态检查量表(MMSE)、社会功能活动检查量表(FAQ)分别评价其智能及社会功能状态。结果治疗6个月后,观察组MMSE评分、FAQ评分均较对照组有显著性差异(p<0.05),有效率(73.81%)较对照组(47.50%)明显提高。结论银杏制剂联合培磊能可有效改善血管性痴呆患者的认知及社会功能,能延缓痴呆的发展,而且安全无明显副作用,是一种有效安全、可供选择的治疗方法。 Objective To evaluate the effect and security of ginkgo leaves associated with Pcrenan in the treatment of vascular dementia. Methods Eighty two cases of vascular dementia were randomly divided into ginkgo leaves associated with Perenan treatment group ( observation group) and Piracetam treatment group ( control group) by case - control study. Intelligence and the social function of all patients were evaluated separately by Mini Mental State Examination (MMSE) and Functional Assessment Questionnaire ( FAQ ) before medication and 6 months after medication. Results MMSE and FAQ score of the observation group was significantly higher than the control group(p 〈 0.05 ) ,the efficiency rate was significantly improved ( 73. 81% vs 47.50% ). Conclusion Ginkgo praeparatum associated with Perenan can effectively improve the cognition and social function of vascular dementia patients. Moreover, it can postpone the development of Alzheimcr' s disease without obviously side effect. It' s an effective and safe therapy method to select.
作者 江炬
出处 《现代医院》 2009年第8期56-57,共2页 Modern Hospitals
关键词 银杏叶片 培磊能 血管性痴呆 临床疗效 Ginkgo leaves, Perenan, Vascular dementia, Clinical effect
  • 相关文献

参考文献5

二级参考文献21

共引文献111

同被引文献15

  • 1Camicioli R,Fisher N.Progress in clinical neurosciences:Parkinson's disease with dementia and dementia with Lewy bodies.Can J Neurol Sci,2004,31:7-21.
  • 2DeFeudis FV,Drieu K.Ginkgo biloba extract (EGb 761) and CNS functions:basic studies and clinical applications.Curr Drug Targets,2000,1(1):25-58.
  • 3McCarney R,Fisher P,Iliffe S,et al.Ginkgo biloba for mild to moderate dementia in a community setting:a pragmatic,randomised,parallel-group,double-blind,placebo-controlled trial.Int J Geriatr Psychiatry,2008,23(12):1222-1230.
  • 4Petersen RC,Doody R,Kurz A,et al.Current concepts in mild cognitive impairment.Arch Neurol,2001,58(12):1985-1992.
  • 5Petersen RC,Smith GE,Waring SC,et al.Mild cognitive impairment:clinical characterization and outcome.Arch Neurol,1999,56(3):303-308.
  • 6Papapetropoulos S,Lieberman A,Gonzalez J,et al.Can Alzheimer's type pathology influence the clinical phenotype of Parkinson's disease? Acta Neurol Scand,2005,111(6):353-359.
  • 7Liu CY,Wang SJ,Fuh JL,et al.The correlation of depression with functional activity in Parkinson's disease.J Neurol,1997,244(8):493-498.
  • 8Leentjens AF,Verhey FR,Lousberg R,et al.The validity of the Hamilton and Montgomery-Asberg depression rating scales as screening and diagnostic tools for depression in Parkinson's disease.Int J Geriatr Psychiatry,2000,15(7):644-649.
  • 9Leentjens AF,Verhey FR,Luijckx GJ,et al.The validity of the Beck Depression Inventory as a screening and diagnostic instrument for depression in patients with Parkinson's disease.Mov Disord,2000,15(6):1221-1224.
  • 10Simonian NA,Coyle JT.Oxidative stress in neurodegenerative diseases.Annu Rev Pharmacol Toxicol,1996,36:83-106.

引证文献1

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部